Skip to main content
Evogene Ltd. logo

Evogene Ltd. — Investor Relations & Filings

Ticker · EVGN ISIN · IL0011050551 TA Professional, scientific and technical activities
Open in API
Filings indexed 1,607 across all filing types
Latest filing 2026-05-20 Share Issue/Capital Cha…
Country IL Israel
Listing TA EVGN

About Evogene Ltd.

https://evogene.com/

Evogene Ltd. is a computational biology company that leverages artificial intelligence and big data to discover and develop novel life-science products. The company's proprietary Computational Predictive Biology (CPB) platform is designed to optimize the probability of success and reduce the time and cost of development. Evogene operates in the fields of human health, agriculture, and industrial applications. Its technology is organized into three AI-driven engines tailored for specific product types: MicroBoost AI for microbe-based products, ChemPass AI for small molecule-based products, and GeneRator AI for products based on genetic elements. The company's business model involves supporting subsidiary companies that focus on specific commercial fields, utilizing Evogene's technology to bring innovative products to market.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT NO. 1
Share Issue/Capital Change Classification · 85% confidence The document is a Prospectus Supplement filed under SEC Rule 424(b)(3) amending the Form F-1 prospectus for an equity offering (2,446,707 ordinary shares). It is not a simple earnings release or interim/annual report but rather a capital markets document updating and supplementing the share issuance prospectus. This falls under the category for share issuance/capital changes (SHA), not a basic financing update or fallback regulatory notice.
2026-05-20 English
PROSPECTUS SUPPLEMENT NO. 1
Report Publication Announcement Classification · 95% confidence The document is a brief announcement filed via the Israel Securities Authority and Tel Aviv Stock Exchange (reported via MAGNA). It states that a report (“PROSPECTUS SUPPLEMENT NO. 1”) is attached and scheduled for publication, but does not include substantive content of the supplement itself. Under the “menu vs meal” rule, this is an announcement of a report’s release rather than the report itself, so it is classified as a Report Publication Announcement.
2026-05-20 English
Evogene Reports First Quarter 2026 Financial Results
Earnings Release Classification · 93% confidence The document is a Form 6-K furnishing the company’s Q1 2026 press release and slide deck, but the bulk of the text is the “Evogene Reports First Quarter 2026 Financial Results” press release containing key quarterly highlights and initial financial results. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). Q1 2026
2026-05-20 English
Evogene Reports First Quarter 2026 Financial Results
Report Publication Announcement Classification · 85% confidence The document is a short notice under the Israel Securities Authority / Tel Aviv Stock Exchange rules announcing that an interim/quarterly report (“Evogene Reports First Quarter 2026 Financial Results”, EVGN_6K_PR_isa.pdf) is attached or will be published at a future time. It contains no substantive financial statements itself, only a link to an attached PDF and scheduling details, fitting the criteria for a Report Publication Announcement.
2026-05-20 English
424B3
Regulatory Filings
2026-05-20 English
6-K
Regulatory Filings
2026-05-20 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.